HCP

Lactobacillus paracasei

Lpc-37™

Grant JR, Stothard P. The CGView Server: a comparative genomics tool for circular genomes. Nucleic Acids Res. 2008;36:W181-W184.

Lpc-37™ Introduction

 L. paracasei Lpc-37™ has been studied alone or in combination with other strains. It is frequently studied alongside of NCFM®, Bi-07™, and Bl-04® as part of the HOWARU® Restore blend for digestive health.1 Lpc-37™ has been cited in more than 60 scientific publications, including 18 clinical trials. It has a long history of safe use, is well suited for intestinal survival, and has strong adhesion to intestinal cell lines and pathogen inhibition.2,3 

43 In vitro through product functionality studies

+17

Clinical trials

HEALTH-BENEFIT AREA SUPPORTED DOSING (CFU) STUDY REFERENCE
Dysbiosis restoration 17 billion (equal parts) Lpc-37™, Bi-07™, NCFM®, Bl-04® Ouwehand AC, et al. Vaccine. 2014;32(4):458-463.

For additional information, visit our Lpc-37™ bibliography

REFERENCES:
1. Ouwehand AC, DongLian C, Weijian X, et al. Probiotics reduce symptoms of antibiotic use in a hospital setting: a randomized dose response study. Vaccine. 2014;32:458-463. 2. Ding WK, Shah NP. Acid, bile and heat tolerance of free and microencapsulated probiotic bacteria. J Food Sci. 2007;72:M446-450. 3. Gibson GR, McCartney AL, Rastall RA. Prebiotics and resistance to gastrointestinal infections. Br J Nutr. 2005;93(Suppl. 1):S31-34.
The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
ARE YOU A HEALTHCARE PROFESSIONAL?
YES
NO